For this study, GBOs from five patients with a hypermethylated MGMT promoter, indicative of sensitivity to alkylating chemotherapy, were selected, along with one GBO population from a patient with a glioblastoma with an unmethylated MGMT promoter (Fig 1E) (For details on the method used to determine MGMT promoter methylation levels, see Schmidt et al. [38]). This evidence concerns the gene MGMT and glioblastoma.